Eventide Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Eventide Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-743,000	Closed	-$17.6M	–	138
2019 Q3	$17.6M	Hold	743,000	–	–	0.58%	60
2019 Q2	$22.3M	Buy	743,000 +383,100	+106%	+$8.78M	0.68%	54
2019 Q1	$8.06M	Sell	359,900 -28,100	-7%	-$604K	0.28%	80
2018 Q4	$7.06M	Hold	388,000	–	–	0.31%	80
2018 Q3	$7.02M	Hold	388,000	–	–	0.26%	91
2018 Q2	$3.86M	Hold	388,000	–	–	0.16%	96
2018 Q1	$2.06M	Buy	+388,000	New	+$2.77M	0.1%	111
2017 Q4	–	Sell	-100,000	Closed	-$1.46M	–	149
2017 Q3	$1.46M	Hold	100,000	–	–	0.08%	112
2017 Q2	$1.87M	Buy	+100,000	New	+$2.26M	0.12%	98

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eventide Asset Management's RARX Position: Q4 2019 in Review

Eventide Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 743,000 shares — an estimated $17.6M sold.

Eventide Asset Management first reported a position in RARX in Q2 2017 and held it in 9 quarters. The position peaked at $22.3M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Eventide Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Eventide Asset Management sold 743,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $17.6M.
Eventide Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
Eventide Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $22.3M in Q2 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Eventide Asset Management's 13F filing for Q4 2019, filed 29 Jan 2020.